Sequential is a global leader in the skin microbiome field, a team of PhD experts in testing products and their effect on human health. An Innovate UK- and Enterprise Singapore-backed company, with labs in Cambridge, New York City and Singapore. Awarded the title "Most Significant" Testing Solution in the Industry - (C&T, 2022). To date, Sequential has amassed over 50,000 human skin microbiome samples and corresponding formulations tested in vivo on the skin. With this vast genomic dataset, Sequential is innovating in inflammatory disease areas, for example – acne, atopic dermatitis and rosacea. They have been previously supported by Innovate UK, Enterprise SG, A*STAR (Genome Institute of Singapore), SOSV, Corundum Systems Biology and other leading organisations.
Sequential Bio: Venture Capital Funding History
Sequential Bio
Sequential Bio
- Life Sciences
- Cambridge, United Kingdom
- £2.6m
- sequential.bio
- Update Information
More venture news
- 13 Nov 2026

Oyster TherapeuticsOyster Therapeutics secures a £45m Series A round from CE-Ventures to develop an oral drug for neurodegenerative diseases
Series ALife Sciences - 10 Nov 2026

Neobe TherapeuticsNeobe lands a £5m seed round led by ARC Ventures to deliver cancer drugs directly into solid tumours
SeedLife Sciences - 9 Nov 2026

PhaSER BiomedicalPhaSER Biomedical secures a £2m grant from Gates Foundation to discover new treatments for neglected diseases
GrantLife Sciences
